Gynecologic Cancer News and Features
Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity in patients with cancer.
Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery.
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT).
Oral contraceptives protect against endometrial cancer, and the protective benefit lasts for many years after women stop taking the pills.
Use of oral contraceptives, even short-term, offers significant long-term protection against endometrial cancer and the protective effect seems to linger for decades after contraceptive is discontinued.
Gynecologic Cancer Clinical Trials
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Blood Test Indicates Breast Cancer Tumors Developed Resistance to Hormone Treatment
- Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme
- Breakthrough Advance Announced in International Blood Cancer Drug Trial
- Yoga May Reduce Side Effects in Patients Receiving Treatment for Prostate Cancer
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Chemo, Tamoxifen May Increase VTE Risk Among Patients With Breast Cancer
- New Blood Test Improves Screening for Prostate Cancer
- Concurrent Chemoradiotherapy Using Paclitaxel Plus Cisplatin in the Treatment of Elderly Patients With Esophageal Cancer
- International Study Charts Genetic Trajectory for Melanoma
- Risk of Several Autoimmune Diseases Increased in Childhood Cancer Survivors
- Protein Biomarker Assays for Diagnosing Thyroid Cancer May Show Inaccurate Readings
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|